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Actions and metabolism of histamine in glomeruli and tubules of the
human kidney. The effects of histamine on cAMP and cGMP accumu-
lation and the intrarenal metabolism of histamine were studied in
glomeruli and cortical tubules of nine human kidneys. Histamine stimu-
lated cAMP but not cGMP accumulation in glomeruli ( + 100% to +
265%) in a dose- (10 to 10 M range) and time-dependent manner.
This effect of histamine was inhibited by the histamine H2 antagonist
cimetidine but not the H1 antagonist diphenhydramine. Moreover, the
H2 agonist dimparit but not the H1 agonist 2-pyridylethylamine stimu-
lated cAMP accumulation. Histamine had no effect on cAMP or cGMP
accumulation in tubules. Because the content of histamine (=2 x 106
M) in glomeruli was far above the circulating levels of plasma hista-
mine in humans (<10_8 M), we explored whether histamine is formed
in human renal tissue. Incubation of glomeruli with I mi of the his-
tamine precursor L-histidine resulted in an increase in histamine levels
(+6.08 0.5 pmoles/mg protein, N = 7 kidneys) while a marked
drop in histamine levels was observed in tubules (—M3.8 2.4
pmoles/mg protein. N = 7 kidneys). The increase in histamine levels
in glomeruli was abolished by the histidine decarboxylase inhibitor
bromocresine. These results indicate that human glomeruli have his-
tamine H2 receptors, which mediate enhanced cAMP accumulation,
and that glomeruli are major sites of histamine production in the hu-
man kidney. Histamine acting via cAMP may influence glomerular
function of the human kidney.
Effets et métabolisme de l'histamine dans les glomerules et les tubules
de rein humain. Les effets de l'histamine sur l'accumulation de cAMP
et de cGMP, et Ic mdtabolisme intra-rénal de l'histamine ont été
étudiés dans les glomérules et les tubules corticaux de neuf reins
humains. L'histamine stimulait l'accumulation de cAMP mais non celle
de cGMP dans les glomCrules ( + 100% a 265%) de facon dose- (de
l06 a io M) et temps-dCpendante. Cet effet de l'histamine était
inhibé par Ia cimdtidine, antagoniste H2 de l'histamine mais non par Ia
diphenhydramine, un antagoniste H1. En outre, le dimparit, un agon-
iste H2, mais non Ia 2-pyridylethylamine, un agoniste H1, a stimulé
l'accumulation de cAMP. L'histamine était sans effet sur
l'accumulation tissulaire de cAMP ou de cGMP. Parce que Ic contenu
d'histamine dans les glomCrules (2 x l06 M) était bien supérieur aux
niveaux circulants d'histamine plasmatique chez l'homme (<l0 M).
nous avons explore si l'histamine se forme dans Ic tissu humain nor-
mal. L'incubation de glomérules avec 1 mri d'histidine, le prdcurseur
de l'histamine, a entrainC une augmentation des niveaux d'histamine
(+6,08 0,5 pmoles/mg protéines, N = 7 reins) alors quune chute
marquee des niveaux d'histamine dtait ohservCe dans les tubules
(—l3,8 2,4 pmoles/mg protéines, N = 7 reins). L'augmentation
des niveaux d'histamine dans les glomCrules a Cté abolie par Ia
bromocrésine, un inhibiteur de l'histidinedécarhoxylase. Ces résultats
indiquent que les glomCrules humains possCdent des récepteurs H2
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pour l'histamine qui médient Ia stimulation de l'accumulation de
cAMP, et que les glomerules sont les sites principaux de production
d'histamine dans Ic rein humain. L'histamine agissart par
l'intermédiaire du cAMP pourrait influencer Ia fonction glomerulaire
dans le rein huniain.
Several recent observations suggest that the biogenic amine
histamine may play a role in renal pathophysiology [1—9]. In the
rat kidney, histamine has been shown to alter renal hemody-
namics and glomerular microcirculation [2] and to stimulate re-
nm release [3]. In rat glomeruli, histamine elicits a marked in-
crease in 3',5'-adenosine cyclic monophosphate (cAMP) accu-
mulation [4, 5], and histamine receptors linked to adenylate
cyclase are present on glomerular cells [6]. We and others have
recently shown that glomeruli are the major sites of histamine
production in this species [7]. In addition, studies in some ex-
perimental models of glomerular disease strongly suggest a role
for histamine in modulating the renal injury [7, 8]. Very little
information is available on the metabolism and cellular actions
of histamine in the human kidney (HK) [1, 9]. Lindberg, Lin-
dell, and Westling [10] found that minced tissue of human fetal
kidney converted labeled histidine to labeled histamine. Zeller
et al [11] described a diamine oxidase activity in the human re-
nal cortex and medulla. Lindell [12] found that whole renal tis-
sue produces radiolabeled methylimidazole acetic acid from
"C-histamine suggesting that the methylation pathway is also
present in the human kidney. More recent studies provide in-
direct evidence that histamine may be involved in renal pa-
thophysiology in humans. In normal subjects, loading studies
with the histamine substrate L—histidine show an increase in
urine but not blood histamine [13] and provide indirect evi-
dence that the human kidney is capable of histamine produc-
tion. Moore, Thompson, and Glassock [14] found that the uri-
nary and blood levels of histamine are elevated following renal
transplantation in humans. The histamine H2 antagonist cimet-
idine has been reported to cause actual reduction in glomer-
ular filtration rate (GFR) in patients with impaired renal func-
tion [15], implying a role for histamine in modulating renal
function in humans.
Because certain metabolic properties of isolated nephron
segments have been reported to differ in humans compared to
other species [16, 17], the present studies were undertaken to
examine the cellular actions of histamine in isolated glomeruli
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and nonglomerular cortical tissue (tubules) of the human renal
cortex and to localize the site(s) of histamine production in the
human kidney.
Methods
Studies were performed on tissue obtained from nine adult
human kidneys (HK): six cadaver donor kidneys judged unsuit-
able for transplantation, and normal renal tissue obtained from
three surgical nephrectomy samples. All donor kidneys were
initially flushed with ice-cold Collin's solution and then
perfused via the renal artery with purified protein fraction and
immersed in the same solution (in the perfusion apparatus) up
until the time of transfer to the laboratory. The surgical sam-
ples were obtained immediately following nephrectomy. The
data available on the nine patients includes: HK I was from a
51-year-old patient who underwent nephrectomy for a large he-
matoma involving the middle portion and the upper pole of the
kidney; the uninvolved lower pole of the kidney was used. HK
2 was a cadaver donor solitary kidney from a 56-year-old pa-
tient who died in an auto accident. HK 3 was a cadaver donor
kidney from a 44-year-old patient; the cause of death was not
listed. HK 4 was a donor kidney from a 41-year-old patient
who died from a stroke. HK 5 was from a 58-year-old patient
who underwent nephrectomy for a nonobstructing tumor of the
renal pelvis. The renal parenchyma was not involved. HK 6
was a cadaver donor kidney from a 35-year-old patient who
also died in an auto accident. HK 7 was a cadaver donor kid-
ney from a 31-year-old patient who died from head injuries in
an auto accident. HK 8 was a donor kidney from a 5-year-old
patient who died from a traumatic subdural hematoma. HK 9
was from a patient who underwent nephrectomy for a large hy-
pernephroma. An uninvolved piece (as judged by light micros-
copy on a frozen section) of the renal cortex most distant from
the tumor was used.
As soon as the tissue samples became available, they were
immersed in ice-cold modified Kreb's buffer (KRB) of the fol-
lowing composition: 140 mrvt NaCl, 5 ms KCI, 1.2 mM MgSO4,
2.0 mrvi CaCI2, 10 m glucose, 10 m sodium acetate, 2 mM
sodium phosphate, and 20 mM Tris (pH = 7.4), and trans-
ferred to the laboratory. The renal capsule was stripped off the
parenchyma, the kidney was bisected, and the cortical tissue
was dissected with a pair of scissors. All subsequent steps were
performed at 4°C. Glomeruli and nonglomerular cortical tissue
samples referred to here as "tubules" were prepared by a siev-
ing technique as described [5, 18] with minor modifications.
The cortical tissue samples were minced and then pressed
through a stainless steel sieve (212 m) with a metal spoon.
The resulting suspension was passed in succession through
390-, 250-, and l50-m nylon sieves; glomeruli were collected
from the top of the l50-m sieve. The glomerular suspension
was then allowed to settle by gravity for 5 mm and the super-
natant containing small tubular fragments or portions of
glomeruli was aspirated with a Pasteur pipette. Glomeruli were
then resuspended in fresh KRB. The glomerular suspension
was greater than 95% pure as judged by light microscopy. Un-
like rat cortical tissue [5, 7], the human nonglomerular fraction
of the renal cortex fragmented into small tubular segments that
passed through all the sieves, with relatively little material col-
lecting on top of the sieves. Therefore, all the washings sub-
sequent to the first sieving (212 Im) were collected and com-
bined with the material that settled on top of the sieves. The
suspension was pelieted by centrifugation at x 1500g for 20 mm
and resuspended in ice-cold KRB. This nonglomerular suspen-
sion is referred to as "tubules ." he resulting glomerular and
tubular preparations were used for these studies. The bulk of
the cortical and glomerular tissue from HK 1, 2, and 3 was used
for enzyme (histidine decarboxylase) studies (to be reported
elsewhere).
Cyclic nucleotide studies. These studies were performed on
glomerular preparations from six separate kidneys. Incuba-
tions were carried out in a manner analogous to our studies in
the rat [5, 18]. Freshly prepared glomeruli and cortical tubules
(5 to 10 mg wet wt) were resuspended in 100 d of ice-cold
KRB and distributed into 10-mi glass homogenization tubes
(size A, Thomas Scientific Products, Philadelphia, Pennsylva-
nia) containing appropriate volumes of KRB and kept on ice.
Tubes containing the various suspensions were then preincu-
hated at 37°C for 20 mm in a shaking water bath (120
cycles/mm, Dubnoff). At the end of the preincubation, test
agents dissolved in KRB were added in 50-zl volumes. The ad-
dition of test agents was made within a time interval of less
than 10 sec. The final volume of each incubation was 500 l,
and the final concentration of test agents was as indicted in Re-
sults. Tubes were then incubated for an additional 5 mm or as
specified in Results at 37°C in the metabolic shaking water bath.
Drugs and buffer were freshly prepared prior to each experi-
ment. At the end of the incubation, the reaction was termi-
nated by the addition of 500 pJ of ice-cold 10% TCA; the tis-
sue samples were immediately homogenized. A small aliquot of
the whole homogenate was taken for protein determination,
and the rest of the homogenate was centrifuged to precipitate
the proteins. TCA was removed from the supernate by re-
peated extraction (x 5) with water-saturated ether. The remain-
ing ether was then evaporated by heating and samples were
adjusted to neutral pH with 0.5 N NaOH. Aliquots of these ex-
tracts were used for determination of cAMP and cGMP. In one
experiment, the homogenate after the incubation was divided
into two separate aliquots for cAMP and cGMP determination.
Tracer amount of 3[H]-cAMP was added to the respective au-
quot for monitoring recovery. The quantity of 3[H]-cAMP
tracer added for the determination of recovery and that con-
tributed to the final concentration of cAMP was calculated and
subtracted from each sample. Added 3H-cAMP (95% 4.0)
was recovered in the final extract immediately prior to RIA.
Therefore, this step of monitoring the recovery was omitted
from the rest of the experiments.
Cyclic nucleotide determination by RIA was carried out as
originally described by Steiner, Parker, and Kipnis [19] and
modified to increase the sensitivity of cAMP [201 and cGMP
[21] by acetylation and succinylation, respectively. Drugs used
were tested for possible interference with RIA. At the highest
concentration used in this study, none of the drugs interfered
with either cAMP or cGMP assay.
In each experiment, glomeruli and tubules from the same
kidney were incubated on the same day and under identical
conditions. Samples from the same kidney were also proc-
essed for extraction, RIA, and protein determination at the
same time with the same batch of reagents. Protein was deter-
mined by the method of Lowry et al [22] and cyclic nucleotide
data were expressed as picomoles per milligram of protein.
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Histamine content. Tissue samples from two separate kid-
neys (one surgical sample and another cadaver donor kidney)
were used for the determination of histamine content. As soon
as the tissue became available, a small piece of the renal cor-
tex, freshly prepared glomeruli, and tubules were homog-
enized in ice-cold 0.05 M sodium phosphate buffer pH 7.9. A
small aliquot of the homogenate was taken from protein deter-
mination; the rest of the homogenate was heated in boiling wa-
ter for 5 mm and centrifuged at x 12,800g for 30 mm in a mi-
crocentrifuge (Eppendorf). The supernatant was frozen and
stored at —20°C for histamine determination by radioenzy-
matic microassay [23] (see below).
Histamine production studies. These studies were per-
formed on glomerular and tubular preparations from seven
separate kidneys. The incubation of freshly prepared glomeruli
and cortical tubules was carried out in a manner similar in prin-
ciple to our previous studies in the rat [7]. Freshly prepared
glomeruli (SO-p.l aliquots) and cortical tubules (15 to 25 mg wet
wt) suspended in KRB were distributed into l.5-ml microcen-
trifuge tubes (Eppendor kept on crushed ice. The incubation
mixture also contained 0.1 mM pyridoxal phosphate, a co-
enzyme of histidine decarboxylase, the histaminase inhibitor
aminoguanidine (0.01 mM), and 1.0 m L-histidine, the hista-
mine substrate. The final volume of each incubation was
brought up to 200 pA with KRB buffer pH 7.4. In each experi-
ment, control incubations were made using glomerular and tu-
bular suspensions heated in boiling water for 5 mm before re-
agents were added. In some experiments, additional control in-
cubations were carried out in the presence of D-histidine (not
a histamine substrate). Three experiments included incuba-
tions carried out in the presence or absence of the histidine de-
carboxylase inhibitor bromocresine. Tubes were shaken manu-
ally and incubated for 180 mm at 37°C in a water bath. The
tubes were additionally shaken every 30 mm during the incu-
bation. At the end of the incubation, the reaction was stopped
by heating the tubes in boiling water for 5 mm. The tubes were
then frozen and stored at —20°C. Prior to the determination of
histamine, suspensions of glomeruli and tubules were frozen
and thawed in an ethanol/dry ice bath (four times) to insure re-
lease of histamine. Tubes were then centrifuged at x 12,800g
for 30 mm in a microcentrifuge (Eppendorf). The supernate
was transferred to clean tubes. pH was adjusted to 7.9 to 8.0
by the addition of 5 pA of 0.5 N NaOH (optimum pH for the
histamine assay). Protein was determined in the pellets which
were solubilized in 1.0 N NaOH. Histamine was determined on
20 p1 aliquots of the supernate by a specific and sensitive ra-
dioenzymatic microassay [23].
Briefly, this assay uses histamine methyltransferase (HMT),
which methylates histamine to form Nr-methylhistarnine. The
sample or histamine standard (20 jd) is incubated with 10 pi of
guinea pig HMT (2 mg/mI), containing 0.22 pmoles of 3H-his-
tamine, and 0.28 nmoles of '4C SAMe. The final concentra-
tions of the reactants were as follows: 3H-histamine 7.35 n
and '4C-SAMe 9.35 LM. The total reaction volume was 30 pA.
The mixture was incubated for 1 hr at 37°C. The reaction was
terminated by adding 10 1d 2.4 N perchloric acid. The reaction
product Nr-methylhistamine was extracted as described [231
with minor modifications [24]. NaCL (20 pA) saturated 3.3 N
NaOH, and 400 pA of chloroform were added to the tubes.
Tubes were then tightly capped and shaken on a mechanical
shaker (Eppendorf, Brinkmann) for 20 mm. Then they were
centrifuged at >< l2,800g for 2 mm in a microcentrifuge (Ep-
pendorf 5412). The upper aqueous phase was removed by as-
piration, and to the organic phase 100 pA of NaC1 saturated 1 N
NaOH were added. Tubes were shaken for an additional 5 mm
and centrifuged. The NaOH layer was removed carefully by as-
piration. A 300-pA aliquot of the chloroform phase was trans-
ferred to a counting vial; chloroform was evaporated to dry-
ness in a stream of air. Then 5 ml of Aquasol (New England
Nuclear Corp., Boston, Massachusetts) were added, and the
radioactivity of '4C and 3H was counted in a scintillation spec-
trometer (Searle Mark III Liquid Scintillation System, Model
6880, Searle Analytical, Chicago, Illinois) until the SE of count-
ing was 5% or for 20 mm, whichever was shorter. A standard
curve for authentc histamine base was determined for each as-
say. The ratio of '4C/3H is directly proportional to the amount
of unlabeled histamine present in the incubation mixture. The
assay used was linear between 2.5 and 50 pmoles histamine per
sample or standard. Histamine added to boiled tissue extract
was recovered to the extent of 85 to 95%. Values for hista-
mine were expressed as picomoles per milligrams of protein.
Materials
Histamine dihydrochloride, L-histidine, D-histidine, 1-meth-
yl-3-isobutylxanthine (MIX), and diphenhydramine HCI were
purchased from Sigma Chemical Co., St. Louis, Missouri.
Aminoguanidine sulphate was purchased from Eastman Or-
ganic Chemicals, Eastman Kodak Co., Rochester, New York,
Bromocresine (4-bromo-3-hydroxybenzylozyammne diphydro-
gen phosphate) was kindly supplied by Lederle Laboratories,
Division of American Cyanamid Co., Pearl River, New York.
Cimetidine, dimaprit, and 2-pyridylethylamine were kindly
supplied by Mr. C. Porter of Smith, Kline and French, Phila-
delphia, Pennsylvania.
[3H]-cAMP for the measurement of recoveries was pur-
chased from New England Nuclear Corp. Antibodies and l251
labeled antigens for cAMP were from RIA kits purchased from
Schwartz/Mann, Division of Becton, Dickinson and Co., Or-
angeburg, New York. Antibodies and 3H-labeled antigens for
cGMP and S-Adenosyl-L-methionine-['4C-methyl], 55 to 60
mCi/mmole, were purchased from Amersham Corp., Arlington
Heights, Illinois [(/3-side chain label)-3H] histamine was pre-
pared from [(/3-side chain label)-3H1 L-histidine 10 Ci/mmole
(New England Nuclear Corp.) as described [7, 25]. Statistical
significance was determined by analysis of variance.
Results
The effect of histamine on cAMP production was examined
in glomeruli isolated from six separate human kidneys (Table
1). In the presence of 0.5 mii MIX, a phosphodiesterase inhibi-
tor, io M histamine increased cAMP accumulation in all six
glomerular preparations tested. After a 5-mm incubation, the
stimulatory effect of histamine on cAMP accumulation ranged
between 100 to 263% and did not appear to depend on the du-
ration of the perfusion or the source of the tissue (Table 1). The
basal concentration of cAMP and cGMP in glomeruli incu-
bated without MIX was much lower than in the presence of
MIX (0.5 mM). However, even when glomeruli were incubated
with histamine alone (in the absence of MIX), an increase in
cAMP was also observed but was of lower magnitude than in
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Table 1. Effect of histamine on cAMP and cGMP accumulation in isolated human glomerulia
cAMP, pmoleslmg protein cGMP, pmoles/mg protein
Kidney source/no. Basal Histamine % Basal Histamine %
1. Surgical sample NT NT
2. Perfused donor kidney (12 hr)b 5.18 0.1° 13.46 1.2 + 160% 3.73 0.12 5.52 2.41
3. Perfused donor kidney (18 hr)b 2.34 0.1 6.16 0.1 +263% 4.81 0.1 4.70 0.1
4. Perfused donor kidney (46 hr)b NT NT
5. Surgical sample 2.98 0.2 7.82 0.9 + 162% 4.22 0.8 4.10 0.3
6. Perfused donor kidney (16 hr)b 7.42 0.3 25.76 0.8 +247% 8.33 0.2 8.89 1.1
7. Perfused donor kidney (36 hr)' 5.80 0.4 11.61 0.1 + 100% 5.89 1.9 5.31 1.6
8. Perfused donor kidney (12 hr)b 4.48 0.1 11.44 1.3 + 155% 5.19 1.5 6.74 0.3
9. Surgical sample NT NT
+48%
—2%
—3%
+7%
—10%
+30%
4.70 0.3° 12.7 1.2" 181 10% 5.36 0.3 5.87 0.3 12 4%
Abbreviation: NT, not tested.
a Isolated glomeruli were incubated for 5 mm in the presence of 0.5 mM MIX.
b The number of hours in parentheses denotes perfusion time.
Values represent sample means SEM of duplicate incubation samples each assayed in duplicate.
"The value is significantly different from basal values (without histamine), P < 0.05 or higher degree of significance (paired t test).
Table 2. Effect of histamine on cAMP and cGMP accumulation in isolated glomeruli and tubules of HK 3a
Glomeruli Tubules
Histamine Histamine
Basal (10—n M) % Basal (l0 M) %_-
cAMP,pmoles/mg protein 2.34b 0.031 6.163±0.103 +263% 1.18 1.425
cGMP,pmoles/mg protein 4.813 0.093 4.70 0.10 —2.3% 7.52 0.39 5.73 0.31
+21%
—23.8%
a Isolated glomeruli and tubules were incubated for 5 mm at 37°C in the presence of 0.5 msi MIX.
b The value represents the mean range of duplicate incubation samples that were each assayed in duplicate.
identical incubations carried out in the presence of 0.5 mti
MIX (% + 34%, + 54% and + 74% in HK, 2, 3 and 7, re-
spectively). Histamine did not influence cGMP accumulation in
glomeruli (Table 1), and cAMP nor cGMP in one tubular prepa-
ration tested (Table 2).
Histamine stimulated cAMP accumulation in glomeruli in a
time- and dose-dependent manner. Stimulation was seen as
early as 30 sec and reached a maximum at 5 mm (Fig. 1A). In
three separate glomerular preparations, total cAMP was deter-
mined at 5 mm as a function of histamine concentration. There
was dose-dependent increase in cAMP accumulation between
10—6 to l0— M histamine (Fig. 1B), with half-normal stimula-
tionatS x 105M.
The effect of histamine specific agonists and antagonists on
cAMP accumulation was tested in three separate glomerular
preparations (Fig. 2A). The histamine (l0 M) stimulated
cAMP accumulation was abolished by cimetidine (l0- M), an
H2 antagonist, but not by equimolar concentrations of the H1
antagonist diphenhydramine. Cimetidine (10 M) and diphen-
hydramine (l0 M) alone, had no sigificant effect on cAMP ac-
cumulation. In one glomerular preparation tested (ilK 8), the
/3-adrenergic blocker propranolol (l0 M) also had no effect on
basal cAMP levels or on the stimulatory effect of histamine
(10 M) on cAMP accumulation (data not shown). The effects
of the specific H1 agonist 2-pyridylethylamine and the H2 ago-
nist dimaprit were also compared in the same three separate
glomerular preparations (Fig. 2A). Dimaprit (1O M) caused a
more than twofold increase in cAMP accumulation, while 2-
pyridylethylamine (l0 M) had no effect. Neither histamine
nor histamine specific agonists or antagonists influenced cGMP
accumulation in glomeruli (Fig. 2B). The stimulatory effect of
dimaprit on cAMP accumulation, similar to the effect of his-
tamine, was dose-dependent (Fig. 3A) with half-maximal stimu-
lation achieved at l0 M. Figure 3B shows that cimetidine
inhibits cAMP accumulation in a dose-dependent manner, with
50% inhibition achieved at l0 M, a drug level achieved in the
blood after clinically employed oral doses [26]. Equimolar con-
centrations of diphenhydramine, on the other hand, had no ef-
fect on cAMP accumulation.
The concentration of circulating histamine in human plasma
(<10 M) is more than two orders of magnitude lower than the
concentration (10-6 M) that elicited enhanced cAMP accumu-
lation in glomeruli. Therefore, histamine content was deter-
mined in the renal cortex, glomeruli, and tubules of the same
kidney. Histamine content averaged 17.62 2.5 in the cortex,
22.55 1.5 in glomeruli, and 23.29 3.0 in tubules
(pmoles/mg protein; N = 4 samples from ilK 1) and 18.34
3.6 in the cortex, 27.8 3.1 in glomeruli, and 31 6.5 in tu-
bules (pmoles/mg protein; N = 4 samples from HK 2). These
tissue levels of histamine markedly exceed plasma levels. To
determine the source of histamine in the human renal cortex,
glomeruli and tubules isolated from the same kidneys were in-
cubated with the histamine substrate L-histidine and histamine
levels were determined. Incubations with 1 mtvt L-histidine
(Fig. 4A) resulted in a significant increase in histamine levels
in seven separate glomerular preparations tested (+ M.08
0.5 pmoles/mg protein). Unlike incubations with L-histidine,
incubations of glomeruli with D-histidine (not a precursor of
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Fig. 1. A Time course of the eff'ect of histamine on cAMP accumula-
tion. isolated glomeruli from HK 7 and 8 were incubated for various
time periods at 37°C. Total cAMP was determined by RIA. For details
see Methods. Points indicate the mean SEM of data from four incu-
bation samples (two from each kidney). Each sample was assayed in
duplicate. B Dose-response curve for the ejfrct qf histamine on cAMP
and cGMP accu,nulation. isolated glomeruli from HK 5, 6, and 7 were
incubated for 5 mm at 37°C. Total cAMP and cOMP were determined
by RIA. For details see Methods. Points indicate the mean SEM of
data from six separate incubation samples (two from each kidney), with
the exception of the io- M (four separate incubation samples). Each
sample was assayed in duplicate.
histamine) did not result in change in histamine levels (Fig. 4B).
In contrast to glomeruli, suspension of cortical tubules incu-
bated with L-histidine (Fig. 4A) under identical conditions as
glomeruli showed no increase but rather a sharp decline in his-
tamine levels (—M3.8 2.4 pmoles/mg protein). A similar
drop in histamine levels were observed in tubules incubated
with D-histidine (Fig. 4B).
To test whether the differences in the ability of glomeruli or
tubules to accumulate histamine was due to a different rate of
histamine synthesis rather than to differential catabolism or
other factors that may influence histamine levels, the effect of
bromocresine, an inhibitor of histidine decarboxylase [27], on
histamine accumulation was examined. In three separate
preparations tested (Fig. 5), the addition of bromocresine abol-
ished the accumulation of histamine in glomeruli incubated
with L-histidine but had no effect on histamine levels in tu-
bules incubated under identical conditions.
Discussion
These studies demonstrate that the cAMP system in isolated
human glomeruli is sensitive to stimulation by histamine and
that glomeruli are sites of active histamine synthesis within the
human renal cortex. The magnitude of the stimulatory effect of
histamine on cAMP accumulation does not appear to be re-
lated to the source of tissue (surgical sample vs. perfused ca-
daver donor kidney) nor to the duration of the perfusion. Of in-
terest is that glomeruli isolated from kidneys perfused for as
long as 18 hr showed similar or higher responsiveness in terms
of cAMP accumulation as glomeruli isolated from freshly ob-
tained surgical samples. Whether this difference in responsive-
ness to histamine represents inherent individual variation, al-
teration in the levels of the cAMP substrate ATP or changes in
the activities of adenylate cyclase or cAMP phosphodiesterase
28] during the perfusion procedure or clamping of the renal ar-
tery prior to the nephrectomy cannot be determined from our
studies.
The effect of histamine on cAMP accumulation is dose-de-
pendent; the concentration of histamine (=°5 X 10 M) elic-
iting a half-maximal elevation in cAMP levels (reflecting in-
directly the affinity of the receptor for histamine) approxi-
mates the concentration required for half-maximal stimulation
of cAMP accumulation in human parathyroid tissue [29] and
the apparent Km of histamine-sensitive adenylate cyclase in hu-
man gastric mucosa [30]. Several criteria suggest that the ef-
fect of histamine is mediated by distinct histamine receptors.
Inhibition of the stimulatory effect of histamine on cAMP ac-
cumulation by cimetidine but not by diphenhydramine or pro-
pranolol indicates that the effect of histamine is mediated by an
H2 receptor linked to adenylate cyclase that is also distinct
from the B-adrenergic receptor. This conclusion is supported
further by the finding that the H2 receptor agonist dimaprit also
stimulates cAMP production in glomeruli in a dose-dependent
manner. In contrast, the histamine H1 agonist 2-pyridyl-
ethylamine at equimolar concentrations had no effect on cAMP
accumulation. While the present studies focused on glomeruli,
the limited observations showing no effect of histamine on
cAMP or cGMP accumulation in cortical tubules suggest that
the presence of histamine receptors in the human renal cortex
is a distinct feature of glomeruli. The cell type or types within
the renal glomerulus bearing histamine receptors remains to be
identified. a
These studies in human glomeruli differ from previous ob-
servations [4, 5] on the effect of histamine on cyclic nucleo-
tides in rat glomeruli in two respects. First, the increase in
cAMP accumulation in response to histamine is lower in hu-
man glomeruli as compared to rat glomeruli. Second, hista-
mine had no effect on cGMP accumulation in human glomeruli
even after 2-mm incubations (data not shown), unlike the small
but consistent increase in cGMP levels in response to hista-
mine observed in the rat. Whether these differences could be
accounted for by species or age differences or the manner in
which the kidneys were handled prior to the glomerular isola-
tion cannot be determined from our experiments. If the effect
of histamine on cGMP in rat glomeruli is secondary to the in-
hibitory effect of generated cAMP on cGMP phosphodiester-
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Fig. 2. A and B Effects of histamine and
histamine-specific agonists and antagonists on
cAMP (A) and cGMP (B) accumulation.
Isolated glomeruli from HK 5, 6, and 7 were
incubated for 5 mm at 37°C (in the presence
of 0.5 mrvi MIX). Total cAMP and cGMP
were measured by RIA. For details see
Methods. Each bar represents mean SEM of
data from six separate incubation samples
(two from each kidney). Each sample was
assayed in duplicate. Asterisks denote values
significantly different from basal value (MIX
alone) at P < 0.05 or higher degree of
significance (analysis of variance).
Abbreviations are: H, histamine; Dimap,
dimaprit (H2 agonist); PEA, 2-
pyridylethylamine (H1 agonist); Diph,
diphenhydramine (H1 antagonist); Cim,
cimetidine (H2 antagonist).
Assuming that tissue content of water is about 80% of wet weight
131], the estimated histamine concentration in human glomerular tis-
sue fluid would be about 2 nmoles/ml of tissue water or 2 x l0 M.
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ase, as suggested by Torres et a! [4], the absence of such an
effect in human glomeruli may be accounted for by the lesser
increase in cAMP in response to histamine.
In addition to the presence of histamine receptors, human re-
nal cortical tissue contains relatively high levels of histamine.'
While these concentrations of histamine [1] probably underesti-
mate its in situ concentration, they are still within the range ca-
pable of eliciting an increase in cAMP in glomeruli. Normal cir-
culating levels of plasma histamine (< 108 M) [32] on the other
hand are at least 100 times lower than the minimal concentra-
tion of histamine capable of stimulating cAMP accumulation in
this tissue in vitro, and plasma levels sufficient to have a stimu-
latory effect on glomeriilar cAMP system are unlikely to be
+ +
Diph Cim
(10 4M( (104M(
achieved in plasma since small elevations in plasma histamine
evoke numerous and severe systemic reactions in humans [13,
33]. Endogenous histamine is more likely therefore to influ-
ence glomerular function than circulating histamine, However,
the extent to which endogenous histamine is quantitatively ac-
cessible to histamine receptors remains to be determined.
There are two potential sources of histamine in renal tissue
[27]. Histamine may be synthesized locally from L-histidine or
it may conceivably be extracted from the arterial blood and
concentrated in the tissue. Our finding that incubation with L-
histidine but not D-histidine increases histamine levels in
glomeruli but not in cortical tubules incubated under identical
conditions suggests that local synthesis in glomeruli is the ma-
jor source of histamine in this nephron structure. This conclu-
sion is supported by the observation that the histidine de-
carboxylase inhibitor bromocresine abolished the increase in
histamine levels observed in glomeruli. The relatively high lev-
els of histamine in cortical tubules varies with our recent find-
ings in the rat [71 where the histamine levels in cortical tubules
Antagonist, M
Fig. 3. A Dose-response curve (f the effects of histamine and hista-
mine agonists on cAMP and cGMP accumulation. Isolated glomeruli
from HK 7 were incubated for 5 mm at 37°C, with increasing concen-
tration of agonists (in the presence of 0.5 mt MIX). Total cAMP and
cGMP were determined by RIA. Far details see Methods. Points rep-
resent the mean of four determinations from two incubation samples.
The range for the incubation samples was 29% or less. Symbols are:
, histamine; •—I, pyridylethylamine; A— —A, dimaprit.
B Dose-response curve of the effects of histamine antagonists on his-
tamine-stimulated cAMP accumulation. Isolated glomeruli from HK 8
were incubated for 2 mm at 37°C with 10 M histamine and increas-
ing concentration of antagonists (in the presence of 0.5 msi MIX).
Points represent the mean range of four determinations from two in-
cubation samples. Symbols are: —•, cimetidine; 0 0, diphen-
hydramine.
Boiled D-hlst Boiled D-hist
Fig. 4. A Histamine content in glomeruli and tubules in control (boiled)
incuhations and after incubation with 1.0 mM L-histidine for 180 mm
at 37°C. All incubations contained 0.1 ms'i pyridoxal phosphate and
0.01 mM aminoguanidine. Each point indicates mean range of at
least two incubation samples from each kidney. Each sample was as-
sayed in duplicate. Numbers between parentheses indicate kidney
sample (for key see Table 1). The mean histamine level (pmoles/mg
protein) in boiled glomeruli was 18.1 1.1 and in incubated glomeruli
24.19 1.3 (mean SEM of seven experiments; P < 0,05 analysis of
variance). Corresponding levels in tubules (pmoles/mg protein) were
42.2 3.4 and 26.43 1.9 (mean SEM of seven experiments; P <
0.05 analysis of variance). B Histamine content in gloineruli and tu-
bules in control (boiled) incubations and after incubation with 1.0 mM
D-histidine (not a histamine substrate) for 180 mm at 37°C. All incu-
bations contained 0.1 msi pyridoxal phosphate and 0.01 m amino-
guanidine. Each point indicates mean range of data from two incu-
bation samples from each kidney. Each sample was assayed in dupli-
cate. Numbers between parentheses indicate kidney samples (for key
see 'fable 1). Histamine levels (pmoles/mg protein) in boiled glomeruli
was 21.07 2.36 and in incubated glomeruli 20.45 2.42 (mean
SEM of four experiments). Corresponding levels in tubules (pmoles/mg
protein) were 38.1 7.2 and 29.3 4.1 (mean SEM of four experi-
ments).
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were much lower than that in glomeruli, The reason for this
discrepancy is not clear. Several factors may influence hista-
mine levels during the perfusion or the nephrectomy, such as
changes in the activity of the synthesizing or degrading en-
zymes or even influx or effiux of histamine from the tissue.
Furthermore, the nonglomerular fraction of the renal cortex re-
ferred to here as "tubules" represents not only material that
sedimented on top of the sieves, but also all nonglomerular cor-
tical tissue which might substantially differ in its cellular con-
tent (interstitial cells or mast cells) from the "tubular" fraction
in the rat studies. Therefore, whether or not a similar pattern
of distribution of histamine exists in situ in the human kidney
tubules or glomeruli cannot be determined from these studies.
The sharp decline in histamine levels observed when tubules
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Fig. 5. Changes in histamine content in glomeruli and tubules in con-
trol (boiled) incubations and after incubations with 1.0 mw L-histidine
for 180 mm at 37°C in the absence (—) and in the presence ( ) of
0.1 mM bromocresine. All incubations contained 0.1 msi pyridoxal
phosphate and 0.01 msi aminoguanidine. Incubations were carried out
for 180 mm at 37°C. Each point indicates the mean range of two in-
cubation samples from each kidney. Each sample was assayed in du-
plicate. Numbers between parentheses indicate kidney sample (for key
see Table 1).
are incubated with L-histidine (similar to those with D-histi-
dine) excludes tubular synthesis of histamine as a major source
of histamine in the human kidney. Active uptake of circulating
histamine by tubules has been demonstrated in the rat [341 or
in addition histamine synthesized in glomeruli that may par-
tially leak to the peritubular circulation may contribute to tu-
bular histamine content. However, regardless of the presence
and source of histamine in tubules, our studies show that
glomeruli are not only targets for histamine's action on cAMP
but also sites of active synthesis. The cell type(s) within the re-
nal glomerulus capable of histamine synthesis is not known. Of
major interest is that human glomeruli are devoid of mast cells
[351, the major site of tissue histamine synthesis. It is conceiv-
able that histamine synthesized in human glomeruli represents
non-mast cell or nascent histamine. The presence of this pool
of histamine was proposed several years ago [36, 37]. Recent
observations in a mouse model deficient in mast cells [381 sup-
port the existence of this pool of non-mast cell histamine in
many tissues including the kidney. The presence of histidine
decarboxylase in isolated cultured endothelial and smooth
muscles from rabbit aorta [39, 40] and the ability of human en-
dothelial cells cultured from umbilical veins to synthesize his-
tamine [41] suggest that glomerular endothelial and perhaps
mesangial (smooth, muscle-like) cells are the source of glomer-
ular histamine synthesis. Precise identification of the cell type
responsible for histamine synthesis awaits studies utilizing
glomerular cells in culture.
The presence of histamine H2 receptors that mediate the en-
hanced cAMP accumulation in human glomeruli suggest that at
least some actions of histamine in this nephron structure may
be mediated by cAMP. Experimental evidence in rat as well as
human glomeruli suggest that certain hormones acting via
cAMP may influence the contractile properties of the glomer-
ular mesangium thereby regulating renal blood flow and GFR
[42]. A similar role of histamine and cAMP in modulating
glomerular microcirculation may be operative in humans. it
should also be emphasized that histamine acting via cAMP may
have numerous other effects, besides its hemodynamic effects,
on both intrinsic glomerular cells or cells infiltrating the
glomerulus in the course of immune-mediated inflammatory in-
jury [43]. For example, histamine may modulate lysosomal en-
zyme release, phagocytosis, release of other mediators, and
metabolism of extracellular glomerular matrix by intrinsic
glomerular cells, as has been demonstrated in extrarenal tis-
sues [43—46]. Furthermore, since histamine receptors have
been demonstrated on a number of inflammatory cells [47] that
have been shown to infiltrate glomeruli in various forms of gb-
merulonephritis in experimental animals [48, 49] and humans
L-hist [50], histamine may profoundly modulate various phases of
glomerular immune inflammatory injury.Bromocresine .Recent studies [511 showing that inflammatory mediators
such as lymphocyte products may enhance histamine produc-
tion in target organs suggest that local synthesis of histamine
may be an important mechanism of histamine availability in
glomeruli, sites of histamine receptors. Pharmacologic manipu-
lation of endogenous histamine and cyclic nucleotides may po-
tentially prove to be effective in influencing the course of im-
mune-mediated glomerular injury.
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